The role of carboxylesterase enzymes in capecitabine therapy by Stoeva, Stanila et al.
Scripta Scientifica Pharmaceutica, 2020;7(1):7-17
Medical University of Varna 7
REVIEWS
THE ROLE OF CARBOXYLESTERASE ENZYMES  
IN CAPECITABINE THERAPY
Stanila Stoeva1, Nikolay Conev2, Petko Marinov1
1Department of Pharmacology, Toxicology and Pharmacotherapy, Faculty of Pharmacy, 
Medical University of Varna 
2Department of Propaedeutics of Internal Diseases, Faculty of Medicine,  
Medical University of Varna
Received: May 8, 2020
Accepted: June 17, 2020
ABSTRACT
INTRODUCTION: Capecitabine (CAP) is an oral antineoplastic pro-drug, whose initial step of activation is 
carboxylesterase (CES) dependent. The main conversion of CAP to 5-DFCR occurs in the liver by CES1 and 
a minor part - in the gastrointestinal tract (GIT) by CES2. Usually, the enteral pro-drug activation is asso-
ciated with the appearance of fluoropyrimidine GIT toxicity, which may be dose-limiting and life-threaten-
ing for the patient. Thus, it is important to clear out the factors that could influence on the activity of both 
CES isozymes.
AIM: The aim of the present study was to present the mechanism of hydrolysis, sources of variability and 
modulation possibilities of CESs, that could affect the treatment with CAP.
MATERIALS AND METHODS: A systematic review of the scientific databases in PubMed, Science Direct 
and Google Scholar was conducted.
RESULTS: The literature data showed up to 89% inter-individual variability in the plasma content of CAP 
and its metabolites. It was also established that factors, such as genetic polymorphisms, age, gender, and 
diseases, are responsible for these variabilities. Enzyme inhibitors and inductors, on the other hand, are 
among the factors that could be controlled and used as reliable modulators for CAP therapy. In fact, some 
authors found that the inhibition of CAP hydrolysis at CES2 level could reduce the common GIT toxicity and 
improve the bioavailability of the pro-drug.
CONCLUSION: In accordance with the individual patient, the CES activity modulation approach could be 
used for the enhancement of the CAP therapeutic index. However, further detailed in vivo researches are 
needed to achieve categorical and applicable results.
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INTRODUCTION
Capecitabine (CAP, N4-pentyloxycarbonyl-5‘-
deoxy-5-fluorocytidine) is an oral antineoplastic 
pro-drug (1). Its development is a strategy for cop-
ing with the undesirable adverse effects of i.v. admin-
istered 5-fluorouracil (5-FU). The pro-drug design 
provides enhanced specificity toward cancer cells, 
reduction of toxicity, and additional treatment costs, 
respectively (2). 
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The activation of CAP includes three-step, en-
zymatically catalyzed process (3). The first step is a 
hydrolytic decomposition of the carbamate func-
tional group by carboxylesterase enzymes. The prod-
uct of this transformation is 5 ′-deoxy-5-fluorocyti-
dine (5-DFCR). The second and third steps are ox-
idative deamination and de-deoxyribosylation re-
actions, catalyzed by cytidine deaminase (CD) and 
thymidine phosphorylase (TP) enzymes, respective-
ly. The final product of this transformation is the cy-
tostatic agent 5-Fluorouracil (5-FU) (Fig. 1) (4). 
The skin, like other organs in the human body, 
As it was mentioned above, carboxylesterase (CES) 
enzymes are responsible for the initial step of CAP 
activation (2,3). They have been shown to be related 
to the efficacy and bioavailability of the pro-drug, as 
well as the manifestation of its toxicity (5). 
Moreover, CESs are involved in the metabo-
lism of over 10% of all clinically administered me-
dicinal substances (6). Therefore, in recent decades, 
these enzymes have been a subject of interest in nu-
merous studies, concerning the biotransformation of 
drugs having ester, thioester, or carbamate function-
al groups, including the discussed here pro-drug. 
The current study aims to present the mecha-
nism of hydrolysis, sources of variability, and mod-
ulation possibilities of carboxylesterase enzymes, re-
lated to the treatment with CAP.
Carboxylesterase Superfamily
Carboxylesterase enzymes (CES, EU 3.1.1.1) are 
identified in species ranging from bacteria to hu-
mans (7,8). They are ubiquitous glycoproteins that 
belong to the α,β-serinehydrolase family (9). CESs 
are mainly expressed in tissues with a barrier func-
tion - epithelium of lungs and gastrointestinal tract 
(GIT), liver, kidneys, skin and other (10). 
CESs play an important role in phase I of en-
dobiotic and xenobiotic metabolism. Their substrates 
are а number of endogenous substances, medicines 
and toxins (Table 1) (11,12).
Fig. 1. A schematic representation of the three-step enzyme conversion of CAP
Table 1. Potential of bexarotene derivatives for the production of dermal metabolites
CES Substrates
Drugs
aspirin, capecitabine, cilazapril, clopidogrel, cocaine, dabigatran etexilate, enalapril, 
heroin, imidapril, irinotecan, meperidine, methylphenidate, olmesartan, orlistat, 
oseltamivir, quinapril, ramipril, temocapril, trandolapril
Endogenous substances acyl-CoA, acylcarnitine, triacylglycerol, cholesterol ester
Other phthalates, benzoates, pyrethroids, pyrethrins, organophosphates, pesticides
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Fig. 2. CES-hydrolysis in humans
Carboxylesterase Mechanism of Hydrolysis 
Carboxylesterase enzymes (CES, EU 3.1.1.1) are 
identified in species ranging from bacteria to hu-
mans (7,8). They are ubiquitous glycoproteins that 
belong to the α,β-serinehydrolase family (9). CESs 
are mainly expressed in tissues with a barrier func-
tion - epithelium of lungs and gastrointestinal tract 
(GIT), liver, kidneys, skin and other (10). 
CESs play an important role in phase I of en-
dobiotic and xenobiotic metabolism. Their substrates 
are а number of endogenous substances, medicines 
and toxins (Table 1) (11,12).
Characteristics of Human Carboxylesterases
Human carboxylesterases are classified into 5 
families: CES1, CES2, CES3, CES4, and CES5. CES1 
and CES2 are found to be principally responsible for 
the biotransformation of xenobiotics (14). Despite 
their common origin, they share only 47-48% amino 
acid homology (15). The significant role of CESs in 
the metabolism and activation of multiple drugs re-
quires elucidation of these specific features.
CES1 is expressed in the liver, adipocytes, and, 
to a lesser extent, in the kidneys, monocytes, lungs, 
GIT, testicles, heart, and macrophages. CES2 is 
mainly expressed in the GIT and less in the kidneys, 
liver, heart, brain, and testicles. For this reason, CES1 
is also called hepatic (hCES), and CES2 is defined as 
human intestinal CES (hiCES) (16). It is supposed 
that the expression of CESs in the intestinal entero-
cytes impedes the absorption of the hydrolyzed sub-
strates (6). Thus, from the perspective of drug me-
tabolism, the administration of CES2 sensitive drugs 
should be considered with a particular caution.
A major characteristic of the detoxification 
properties of human carboxylesterase enzymes is 
their low substrate specificity (17). However, there 
are some differences established in both isozymes 
that could be summarized as follows: CES1 metab-
olizes predominantly small, planar ester substrates, 
with small alcohol groups and bulky acyl residues 
(enalapril, oseltamivir, imidapril, clopidogrel, me-
peridine, as well as the narcotic substances heroin 
and cocaine); CES2 has a greater tendency to hydro-
lyze esters with relatively larger alcohol groups and 
smaller acyl residues (irinotecan, prasugrel, fluta-
mide, fluorescein diacetate) (16,18,19). 
Role of CESs in Activity and Toxicity of CAP
The conversion of CAP to 5-DFCR occurs 
mainly in the liver (20). However, it should not be ne-
glected that a measurable part of the orally admin-
istered CAP could also be degraded in the GIT by 
CES2, cytidine deaminase and thymidine phosphor-
ylase enzymes (3). Therefore, CES2 should be consid-
ered as relevant to the first-pass metabolism and bio-
availability of CAP (21). 
Usually, the pro-drug activation in the gastro-
intestinal tract is associated with the appearance of 
fluoropyrimidine GIT toxicity (diarrhea and mu-
cositis) (22, 23). It is often life-threatening or at least 
dose-limiting for the patient, and therefore requires 
additional medication.
Possible CES-Related Sources of Variability in 
CAP Plasma Exposition 
Pharmacokinetic assays show high inter-in-
dividual variability (up to 89%) in the plasma con-
tent of CAP and its metabolites (24). This is consist-
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ent with the observation that approximately 25% of 
patients experience severe adverse reactions (ADRs), 
such as hand-foot syndrome, diarrhea, anemia, nau-
sea, vomiting, mucositis/stomatitis, and other (25, 
26). In combination with the low therapeutic index 
of the pro-drug, it is difficult to evaluate the benefit/
risk ratio for each patient (27). The identification of 
factors responsible for these deviations would enable 
the prediction of CAP bioavailability, as well as the 
risk of ADRs. This could be a basis for optimizing the 
therapeutic process (28,29). 
Both isozymes (CES1 and CES2) are able to 
hydrolyze CAP to 5-DFCR. Thus, it is reasonable 
to summarize all endo- and exogenous factors that 
could affect their expression (30,31):
CES Gene Polymorphism in CAP Treatment 
According to Vesell ES (2000) from 20% to 95% 
of the drug pharmacokinetic and pharmacodynam-
ic variability is due to genetic factors (32). As a pro-
drug that undergoes a three-step enzyme conver-
sion, CAP is not an exception. It was established that 
genetic polymorphisms can influence the kinetics of 
the antineoplastic agent in the initial step of its acti-
vation. Di L (2019) has defined CES genes as highly 
polymorphic, based on the increasing number of re-
ports of novel single-nucleotide polymorphisms af-
fecting the therapeutic effect of drugs that are acti-
vated or eliminated through this biotransformation 
pathway (12). Literature analysis confirms that CES 
polymorphisms are an important predictor of the 
therapeutic effect and toxicity of CAP (13,17,33,34).
Impact of Age and Gender on CES Activity
Ontogenetic analyses show that the expression 
of CESs increases with the patient’s age. In adults, the 
expression of CES1 and CES2 has been found to be 
∼ 50% and ∼40% higher, respectively, than in chil-
dren (35).
Reports on the impact of gender on CES activi-
ty are insufficient and contradictory. Zhu et al. (2009) 
are among the few researchers who have found that 
CES expression in humans is influenced by sex hor-
mones but not the growth hormone (36). Cassidy J et 
al. (2019) have observed an 87% higher bioavailability 
of CAP in women than in men (37). Other research-
ers do not observe gender as a factor that should be 
considered in antineoplastic therapy (38).
Impact of Diseases on CES Activity
According to Yang et al. (2007) and Unver et al. 
(2018) high IL-6 levels lead to decreased expression of 
CES1 and CES2 (39, 40). Other studies demonstrate 
that type 2 diabetes mellitus, cardiovascular and he-
patic diseases can also reduce CES levels (41, 42, 43). 
Therefore, in clinical practice, the presence of these 
diseases requires a dose adjustment of CAP, as well as 
individual monitoring of each patient (44).
CES Inhibitors and Inducers
As it was presented in Table 1, there is a large 
number of substrates of CES enzymes. The presence 
of some of them is followed by stimulation of tran-
scription of CES genes, leading to increased enzyme 
expression (15). On the other hand, there are sub-
stances that can inactivate allosteric enzyme centres. 
Both of them (inducers and inhibitors) may affect the 
effectiveness of CAP therapy (45).
Inhibitors of Human CESs
Recombinant technologies have given the op-
portunity to screen hundreds of molecules and to 
distinguish those of them that showed activity only 
against human CESs (46). These molecules are usu-
ally classified as substances with a specific or a pan-
inhibitory activity (47). Additionally, some of them 
inhibit reversibly or irreversibly the carboxylesteras-
es’ active center.
Reversible CES Inhibitors
1,2-diones - The number of in vitro studies con-
cerning the pharmacotherapeutic and toxicological 
relevance of this type of CES inhibitors has increased 
in recent years. They are compounds that contain 
1,2-dione functional group (Fig. 3) (48,49,50):
Their activity against CES enzymes exceeds the 
one toward acetylcholinesterase or butyrylcholinest-
erase enzymes (47). QSAR analyses show that, de-
pending on the configuration of the 1,2-dione radi-
cal (cis- or trans-), some specificity is observed with 
respect to the CES1 or CES2 (51). 
Fig. 3. 1,2 – dione structure
Scripta Scientifi ca Pharmaceutica, 2020;7(1):7-17
Medical University of Varna 11
Stanila Stoeva, Nikolay Conev, Petko Marinov 
A number of authors have identified benzyl as 
a potent selective inhibitor of both carboxylesterases 
(52, 53). Janice L. Hyatt et al. (2006) have found that 
this inhibitor reduces the cytotoxic effect of irinote-
can, because it inhibits the conversion to the active 
metabolite SN-38 (54). Tanshinone compounds, iso-
lated from Salvia miltiorrhiza, also exhibit potent in-
hibitory activity against CESs. For example, M. Jason 
Hatfield et al. (2018) have demonstrated the ability of 
these molecules to modulate negatively the metabo-
lism of oseltamivir (55). 
Benzenesulfonamides
Some benzenesulfonate compounds are known 
to exhibit CES2-inhibitory activity (Fig. 4) (56, 57). 
By analogy with 1,2-dione, they also have no activ-
ity against acetylcholinesterases or butyrylcholinest-
erases (58, 59). In this regard, Randy M. Wadkins et 
al. (2004) have reported a suppression of gastroin-
testinal toxicity by irinotecan using benzenesulfon-
amide analogues. The authors have proved that the 
results are due to a selective inhibition of intestinal 
CES2 (56).
Trifluoroketones
Trifluoroketones exhibit strong inhibitory ef-
fects on carboxylesterases with Ki values in the low 
nanomolar range (Fig. 5) (60). Some members of this 
class have activity against other enzymes in the hu-
man body (61, 62). This should be taken into account 
when a selective drug-metabolizing modulation is 
intended.
Fig. 4. Benzensulfonamide structure
Fig. 5. Trifluoroketone structure
Acylglucuronides 
The number of scientific reports describing 
acylglucuronide metabolites as enzyme modulators 
(including toward CESs) is increasing (Fig. 6) (63, 
64). Thereby, Williams et al. (2013) have reported 
that diclofenac-β-D-glucuronide and clopidogrel-β-
D-glucuronide inhibit CES1-mediated hydrolysis of 
4-nitrophenyl acetate (65).
Terpenoids 
Zou LW et al. (2017) have found that the pen-
tacyclic triterpenoids oleanolic acid and ursolic acid 
have a strong inhibitory effect against CES1. Where-
as, the β-boswelic acid exerts strong inhibitory ef-
fects against CES2 (66). In another study, Zou LW 
et al. (2016) have demonstrated that glycyrrheretinic 
acid (a biologically active substance in the roots and 
rhizomes of glycyrrhiza) is a potent CES2-inhibitor 
(67).
Flavonoids
Bavachinin, coryfolin, corylin, neobavaiso-
flavone, corylifol A and corylifolinin contained in 
Fructus psoraleae (Psoralea corylifolia L. - Fabaceae) 
are reported to exhibit inhibitory properties against 
CES1 and CES2 (68, 69).
Another example of flavonoid-induced CES 
modulation is the ethanolic bark extract from white 
mulberry roots. It has been established that com-
pounds contained therein (sanggenone D, kuwanon 
G and sanggenone C) inhibit CES2-mediated hydrol-
ysis of fluorescein diacetate (70).
Fatty acid and cholesterol analogues
Crow et al. (2010) have reported that some nat-
ural fatty acids (myristic acid, myristolic acid, pal-
mitic acid, palmitolic acid, linoleic acid, γ-linoleic 
acid, arachidonic acid) can strongly inhibit the hy-
drolytic activity of recombinant CES1. The authors 
have proven that 27-hydroxycholesterol also shows 
Fig. 6. Acylglucuronide structure
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inhibitory activity against recombinant CES1 and 
CES2 (71,72).
Medicines and excipients 
The ability of CESs to biotransform a large vari-
ety of substances underlies the interactions between 
particular CES substrates, including drugs and/or 
excipients. Fukami et al. (2010) have reported that 
hydrolysis of imidapril (of recombinant CES1) is sig-
nificantly inhibited by statins containing a lactone 
ring (simvastatin, lovastatin), as well as thiazolidine-
diones (troglitazone, rosiglitazone). Similarly, CES2-
mediated hydrolysis of irinotecan can be strongly in-
hibited by both fenofibrate and simvastatin (73). In 
another in vitro study, Xu Yanjiao et al. (2013) have 
demonstrated that the antihypertensive drugs tel-
misartan and nitrendipine inhibit CES1-mediated 
hydrolysis of imidapril, and diltiazem and verapamil 
suppress CES2-hydrolysis of irinotecan (74). The an-
ticholinesterase alkaloid physostigmine suppresses, 
by an identical mechanism, the decomposition of the 
mentioned above anticancer drug (75). The antidiar-
rheal medicine loperamide also demonstrates inhibi-
tory activity against CES2 (76).
The literature review confirms the importance 
of excipients as potential participants in pharma-
cokinetic interactions too. Zhang et al. (2014) have 
reported that sodium lauryl sulphate and polyoxyl 40 
hydrogenated castor oil can significantly inhibit im-
idapril‘s CES1-mediated hydrolysis. In addition, the 
non-ionic surfactant tween 20 and polyoxyl 35 castor 
oil can inhibit irinotecan‘s CES2-mediated hydroly-
sis (77).
Irreversible CES inhibitors
Carbamate compounds, which are widely used 
as insecticides, have been identified as potent inhibi-
tors of acetylcholinesterases (78). Lyudmila G. Tsur-
kan et al. (2013) have proved their ability to inhibit 
CES1 and CES2 activity too (79). Organophosphates 
are another example of acetylcholinesterase and car-
boxylesterase inhibitors (80).
Inductors of Human CESs 
The analysis of the literature data shows that 
there is a small number of studies dedicated to 
CES induction. Xu J et al. (2014) have asserted that 
glucose can stimulate hepatic CES1 expression in 
mice (81). Some antioxidants, such as sulforaphane 
compounds, are found to induce the same isozyme 
(82,83). Medicines with CES-induction properties 
are dexamethasone and phenobarbital (84). 
Possibilities for CES Therapeutic Modulation 
in CAP Treatment
Enzyme inhibitors/inductors are the only bio-
transformation factors that could be controlled and 
used in order to improve the pharmacological pro-
file of a particular drug (85). Examples of successful 
fixed-dose combinations in modern practice are car-
bidopa/levodopa, amoxiclav/clavulanic acid, imipen-
em/cilastatin and others (86). Similarly, the adminis-
tration of CES modulators in combination with CAP 
could be used for a prevention of gastrointestinal tox-
icity in cancer patients.
In this regard, Quinney SK et al. (2005) have re-
ported that loperamide may exert its anti-diarrheal 
properties in CAP-induced GIT toxicity by an ad-
ditional mechanism (76). Authors have proven that 
the opioid agonist is also a potent CES2 inhibitor. As 
a result, the amount of prematurely activated CAP 
(and respectively the formed cytotoxic agent 5-FU) 
in the gut was reduced. Accounting the pharmacoki-
netics of loperamide, an affection of CES1 activity is 
not expected (87). Moreover, the inhibition of CAP 
hydrolysis at CES2 level probably would lead to an 
improvement in its bioavailability. Therefore, mod-
ulation of CES activity could be used for a therapeu-
tic process optimization, according to the individu-
al patient. 
CONCLUSION
There are several factors established that could 
be responsible for the deviation in activity and ex-
pression of CESs. In fact, they may influence the 
pharmacokinetics and efficacy of their drug sub-
strates, such as CAP, which should be taken into ac-
count during the process of cancer treatment. On the 
other hand, the literature review showed that the in-
itial step of CAP activation could be modulated as 
a therapeutic strategy. It was noted that the simul-
taneous intake of CAP and a selective CES2 inhibi-
tor may be used in order to reduce the pro-drug GIT 
toxicity. Тherefore, the encouraging results of these 
findings need further in vivo studies to reveal the full 
potential of the idea of CES modulation for therapeu-
tic purposes.
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